Blueberry-Derived Exosome-Like Nanoparticles Counter the Response to TNF-α-Induced Change on Gene Expression in EA.hy926 Cells.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
10 05 2020
Historique:
received: 16 03 2020
revised: 07 05 2020
accepted: 08 05 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 7 4 2021
Statut: epublish

Résumé

Exosome-like nanoparticles (ELNs) are attracting interest as important vehicles of intercellular communication, both in prokaryotes and eukaryotes. Recently, dietary nanoparticles similar to mammalian exosomes have attracted attention for these features. In particular they appear to be relevant in the modulation of several cellular processes as well as candidate carriers of bioactive molecules (proteins, lipids, and nucleic acids, including miRNAs) with therapeutic value. Herein, we investigated the cellular uptake of blueberry-derived ELNs (B-ELNs) by a human stabilized endothelial cell line (EA.hy926) and the ability of B-ELNs to modulate the expression of inflammatory genes as the response of tumor necrosis factor-α (TNF-α). Our results indicate that 1) EA.hy926 cells internalize B-ELNs in a dose-dependent manner; 2) pretreatment with B-ELNs counters TNF-α-induced reactive oxygen species (ROS) generation and loss of cell viability and modulates the differential expression of 29 genes (fold change > 1.5) induced by TNF-α compared to control; 3) pathway analysis reveals their involvement in a total of 340 canonical pathways, 121 KEGG pathways, and 121 GO Biological processes; and 4) the intersection between differentially expressed (DE) genes and miRNAs contained in B-ELNs unveils a set of candidate target genes, such as prostaglandin I2 synthase (PTGIS), mitogen-activated protein kinase 14 (MAPK14), and phosphodiesterase 7A (PDE7A), for ELNs-contained cargo. In conclusion, our study indicates that B-ELNs can be considered candidate therapeutic carriers of bioactive compounds potentially able to protect vascular system against various stressors.

Identifiants

pubmed: 32397678
pii: biom10050742
doi: 10.3390/biom10050742
pmc: PMC7277966
pii:
doi:

Substances chimiques

MicroRNAs 0
RNA, Messenger 0
Reactive Oxygen Species 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Trends Cell Biol. 2017 Mar;27(3):172-188
pubmed: 27979573
Mol Med Rep. 2016 Aug;14(2):1397-403
pubmed: 27314273
Nutrients. 2020 Feb 13;12(2):
pubmed: 32069862
Methods Mol Biol. 2018;1732:507-517
pubmed: 29480496
Int J Food Sci Nutr. 2019 May;70(3):267-284
pubmed: 30185085
Eur J Pharm Sci. 2017 Feb 15;98:40-50
pubmed: 27664331
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W155-9
pubmed: 21622958
Int J Mol Sci. 2016 Dec 22;18(1):
pubmed: 28025496
Int J Mol Sci. 2013 Mar 06;14(3):5338-66
pubmed: 23466882
Mol Nutr Food Res. 2014 Jul;58(7):1561-73
pubmed: 24842810
Front Pharmacol. 2017 Aug 03;8:464
pubmed: 28824425
Mol Pharm. 2018 Dec 3;15(12):5772-5780
pubmed: 30359033
Life Sci. 2003 Jul 18;73(9):1097-114
pubmed: 12818719
Vascul Pharmacol. 2002 May;38(5):271-3
pubmed: 12487031
Toxicol Lett. 2015 Dec 15;239(3):152-60
pubmed: 26422990
Toxicol Lett. 2016 Dec 15;264:51-58
pubmed: 27793764
Cell Res. 2012 Jan;22(1):107-26
pubmed: 21931358
Eur J Pharmacol. 2016 Jan 5;770:9-15
pubmed: 26607460
Cell Res. 2016 Feb;26(2):217-28
pubmed: 26794868
Curr Hypertens Rev. 2008 Nov;4(4):245-255
pubmed: 20559453
Cell Host Microbe. 2018 Nov 14;24(5):637-652.e8
pubmed: 30449315
Arch Biochem Biophys. 2018 Oct 1;655:18-25
pubmed: 30096293
Mol Pharm. 2019 Jun 3;16(6):2690-2699
pubmed: 31038962
PeerJ. 2018 Jul 31;6:e5186
pubmed: 30083436
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Mol Ther. 2013 Jul;21(7):1345-57
pubmed: 23752315
Mol Nutr Food Res. 2013 Nov;57(11):1979-87
pubmed: 23901008
J Neurosci. 2014 Feb 12;34(7):2583-91
pubmed: 24523548
Biochem J. 2013 Sep 1;454(2):201-8
pubmed: 23772801
Biofactors. 2017 Jan 2;43(1):54-62
pubmed: 27412371
Food Funct. 2019 Feb 20;10(2):529-538
pubmed: 30724295
Biochem Biophys Res Commun. 2000 Aug 2;274(2):415-21
pubmed: 10913353
Mol Ther. 2013 Jul;21(7):1294-6
pubmed: 23812547
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Proteomics. 2018 Feb 20;173:1-11
pubmed: 29197582
Oncotarget. 2015 Aug 14;6(23):19514-27
pubmed: 26098775
Appl Opt. 2010 Dec 1;49(34):6602-11
pubmed: 21124537
Am J Physiol Lung Cell Mol Physiol. 2011 May;300(5):L781-9
pubmed: 21378027
Nucleic Acids Res. 2019 Jul 2;47(W1):W234-W241
pubmed: 30931480
eNeuro. 2017 Apr 21;4(2):
pubmed: 28451639
Tissue Barriers. 2016 Feb 11;4(2):e1134415
pubmed: 27358751
Cancer Lett. 2016 Feb 1;371(1):48-61
pubmed: 26604130
BMB Rep. 2016 Nov;49(11):585-586
pubmed: 27733233
PLoS One. 2016 Jan 22;11(1):e0147034
pubmed: 26799794
Curr Pharm Biotechnol. 2018;19(11):877-885
pubmed: 30332948
Genes Nutr. 2014 Jul;9(4):404
pubmed: 24838260

Auteurs

Mariangela De Robertis (M)

Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Consiglio Nazionale delle Ricerche (CNR), 70126 Bari, Italy.
Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari Aldo Moro, 70125 Bari, Italy.

Angelo Sarra (A)

Department of Science, University of Roma Tre, 00145 Rome, Italy.
CNR-ISC UOS Sapienza, Sapienza University of Rome, 00185 Rome, Italy.

Valentina D'Oria (V)

Bambino Gesù Children's Hospital IRCCS, Research Laboratories, 00146 Rome, Italy.

Francesco Mura (F)

Center for Nanotechnology for Engineering (CNIS), Sapienza University of Rome, 00185 Rome, Italy.

Federico Bordi (F)

CNR-ISC UOS Sapienza, Sapienza University of Rome, 00185 Rome, Italy.
Department of Physics, Sapienza University of Rome, 00185 Rome, Italy.

Paolo Postorino (P)

Department of Physics, Sapienza University of Rome, 00185 Rome, Italy.

Deborah Fratantonio (D)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari Aldo Moro, 70125 Bari, Italy.
Bambino Gesù Children's Hospital IRCCS, Research Laboratories, 00146 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH